BioXcel Therapeutics, Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Product revenue, net | $642K-71.7% | $2.3M+64.2% | $1.4M+268.0% | $375K | — |
| Cost of goods sold | $164K-92.3% | $2.1M+70.1% | $1.3M+6200.0% | $20K | — |
| Research and development | $30.3M-0.6% | $30.4M-63.9% | $84.3M-7.6% | $91.2M+73.1% | $52.7M |
| Selling, general and administrative | $20.5M-40.6% | $34.5M-58.6% | $83.4M+21.3% | $68.8M+26.8% | $54.2M |
| Restructuring costs | $194K-92.1% | $2.4M-41.4% | $4.2M | — | — |
| Total operating expenses | $51.1M-26.5% | $69.5M-59.9% | $173.2M+8.2% | $160.0M+49.6% | $106.9M |
| Loss from operations | -$50.5M+25.0% | -$67.2M+60.9% | -$171.8M-7.6% | -$159.6M-49.3% | -$106.9M |
| Interest expense | $17.0M+12.3% | $15.1M+13.6% | $13.3M+62.1% | $8.2M+20632.5% | -$40K |
| Interest income | -$1.1M+59.0% | -$2.6M+53.9% | -$5.6M-123.5% | -$2.5M-5645.5% | -$44K |
| Other (income) expense, net | $3.5M+117.4% | -$20.2M-5020.1% | -$394K-192.3% | $427K | — |
| Net loss | -$69.9M-17.3% | -$59.6M+66.7% | -$179.1M-8.0% | -$165.8M-55.0% | -$106.9M |
| Basic net loss per share attributable to common stockholders (in dollars per share) | -$5730.00+75.6% | -$23510.00+76.1% | -$98330.00-1561.0% | -$5920.00-46.2% | -$4050.00 |
| Diluted net loss per share attributable to common stockholders (in dollars per share) | -$5730.00+75.6% | -$23510.00+76.1% | -$98330.00-1561.0% | -$5920.00-46.2% | -$4050.00 |
| Weighted average shares outstanding - basic (in shares) | 12.2M+381.6% | 2.5M+39.2% | 1.8M-93.5% | 28.0M+6.2% | 26.4M |
| Weighted average shares outstanding - diluted (in shares) | 12.2M+381.6% | 2.5M+39.2% | 1.8M-93.5% | 28.0M+6.2% | 26.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | 2026-05-22 | Yocca Frank | Chief Scientific Officer | Sale | 6,845 | $1.08 | $7K | 26.2K | View | |
| 2026-05-20 | 2026-05-22 | Rodriguez Javier | See Remarks | Sale | 6,560 | $1.08 | $7K | 26.8K | View | |
| 2026-05-20 | 2026-05-22 | Mehta Vimal | Director & CEO and President | Sale | 19.4K | $1.09 | $21K | 69.6K | View |
Informational purposes only, not investment advice.